Literature DB >> 8550956

Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression.

M Maes1, H Y Meltzer, E Bosmans, R Bergmans, E Vandoolaeghe, R Ranjan, R Desnyder.   

Abstract

Recently, it was found that major depression may be accompanied by significant changes in cell-mediated and humoral immunity. The purpose of this study was to investigate the plasma concentrations of interleukin (IL)-6, soluble IL-6 receptor (sIL-6R), sIL-2R and transferrin receptor (TfR) in patients with major depression in an acute phase of illness, in remission and during antidepressive treatment. Plasma concentrations of IL-6, sIL-6R, sIL-2R and TfR were significantly higher in major depressed subjects than in healthy controls. In major depressed subjects, but not in normal controls, there were significant positive correlations between the plasma concentrations of IL-6 and sIL-6R, IL-6 and sIL-2R, IL-6 and TfR, and between sIL-2R and TfR. Subchronic treatment with antidepressive drugs, such as fluoxetine or tricyclic antidepressants, did not significantly affect plasma IL-6, sIL-6R, sIL-2R or TfR. The latter did not significantly differ between major depressed patients in an acute phase of illness or in complete clinical remission. It is suggested that: (1) a coordinated and upregulated production of IL-6, sIL-6R, sIL-2R and TfR may constitute a trait marker of major depression; and that (2) an upregulated production of IL-6 may represent a contributing factor to the various immune disorders encountered in major depression and maybe to the pathophysiology or pathogenesis of that illness.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8550956     DOI: 10.1016/0165-0327(95)00028-l

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  126 in total

1.  Serotonin-immune interactions in major depression: lower serum tryptophan as a marker of an immune-inflammatory response.

Authors:  M Maes; R Verkerk; E Vandoolaeghe; F Van Hunsel; H Neels; A Wauters; P Demedts; S Scharpé
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1997       Impact factor: 5.270

2.  The concept of depression as a dysfunction of the immune system.

Authors:  Brian E Leonard
Journal:  Curr Immunol Rev       Date:  2010-08

3.  The influences of cytokines as a possible substrate for the psychological effects of immunomodulation therapy in multiple sclerosis.

Authors:  N N Spirin; D S Kasatkin
Journal:  Neurosci Behav Physiol       Date:  2009-01

4.  Depression, cytokines, and pancreatic cancer.

Authors:  William Breitbart; Barry Rosenfeld; Kristen Tobias; Hayley Pessin; Geoffrey Y Ku; Jianda Yuan; Jedd Wolchok
Journal:  Psychooncology       Date:  2013-10-18       Impact factor: 3.894

Review 5.  Toward Omics-Based, Systems Biomedicine, and Path and Drug Discovery Methodologies for Depression-Inflammation Research.

Authors:  Michael Maes; Gabriel Nowak; Javier R Caso; Juan Carlos Leza; Cai Song; Marta Kubera; Hans Klein; Piotr Galecki; Cristiano Noto; Enrico Glaab; Rudi Balling; Michael Berk
Journal:  Mol Neurobiol       Date:  2015-05-02       Impact factor: 5.590

Review 6.  Neurobiology of resilience in depression: immune and vascular insights from human and animal studies.

Authors:  Katarzyna A Dudek; Laurence Dion-Albert; Fernanda Neutzling Kaufmann; Ellen Tuck; Manon Lebel; Caroline Menard
Journal:  Eur J Neurosci       Date:  2019-09-13       Impact factor: 3.386

7.  Sustained low-grade pro-inflammatory state in unmedicated, remitted women with major depressive disorder as evidenced by elevated serum levels of the acute phase proteins C-reactive protein and serum amyloid A.

Authors:  Mitchel A Kling; Salvatore Alesci; Gyorgy Csako; Rene Costello; David A Luckenbaugh; Omer Bonne; Roman Duncko; Wayne C Drevets; Husseini K Manji; Dennis S Charney; Philip W Gold; Alexander Neumeister
Journal:  Biol Psychiatry       Date:  2006-12-18       Impact factor: 13.382

8.  Associations of Serum Cytokine Receptor Levels with Melancholia, Staging of Illness, Depressive and Manic Phases, and Severity of Depression in Bipolar Disorder.

Authors:  Marcin Siwek; Magdalena Sowa-Kućma; Krzysztof Styczeń; Paulina Misztak; Rafał J Nowak; Bernadeta Szewczyk; Dominika Dudek; Janusz K Rybakowski; Gabriel Nowak; Michael Maes
Journal:  Mol Neurobiol       Date:  2016-09-23       Impact factor: 5.590

9.  Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment.

Authors:  S J Bull; P Huezo-Diaz; E B Binder; J F Cubells; G Ranjith; C Maddock; C Miyazaki; N Alexander; M Hotopf; A J Cleare; S Norris; E Cassidy; K J Aitchison; A H Miller; C M Pariante
Journal:  Mol Psychiatry       Date:  2008-05-06       Impact factor: 15.992

Review 10.  Glucocorticoid dysregulations and their clinical correlates. From receptors to therapeutics.

Authors:  Andrea H Marques; Marni N Silverman; Esther M Sternberg
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.